hotspot -WSS

hotspot

author：hotspot 2025-09-27 15:57:57 - browse：65

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How digital tools helped lower hypertension in marginalized patients

Wikipedia

WSS

Key House Republican on health care plans exit from Congress

FDA seeks to regulate lab

Did you have Obamacare on your GOP debate bingo card?

FDA seeks to regulate lab

Medical mystery: When a cough is not just a cough

Shingles, which affected Dianne Feinstein, is on the rise

hotspot

hotspot

entertainment

Supreme Court strikes down use of affirmative action

Medical mystery: When a cough is not just a cough

Supreme Court strikes down use of affirmative action

PhRMA lawsuit over Medicare drug price negotiation tossed

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WHO recommends dropping component of many flu vaccines

Bright Health sells Medicare Advantage business to Molina

Covid vaccines: Private market messier than government rollout

BioMarin wins approval for gene therapy to treat hemophilia A

Key House Republican on health care plans exit from Congress

knowledge

Paxlovid should be available without a positive Covid test

PhRMA lawsuit over Medicare drug price negotiation tossed

Sudafed saga points to U.S. issues with evaluating older drugs

Medicare Advantage proposed rates disappoint insurers

Biogen Alzheimer’s drug launch off to slow start

Biogen shutters digital health group, ends Apple study, in cost cutting move

Wikipedia

hotspot

Wikipedia

focus